Aseptic loosening following primary total hip replacement Musculoskeletal Diseases
Conditions
Interventions
MiRNAs will be isolated, observed and compared from peripheral blood samples from control patients who are undergoing primary total hip arthroplasty (THA) due to degenerative hip osteoarthritis (group
Sponsors
University of Patras
Eligibility
Sex/Gender
All
Age
40 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Aged >40 years old 2. Patients undergoing primary total hip arthroplasty (THA) due to degenerative hip osteoarthritis (Group A) 3. Patients who underwent primary THA, without clinical and radiological evidence of periprosthetic osteolysis and aseptic loosening (Group B) 4. Patients undergoing revision surgery after primary THA, with clinical and radiological evidence of periprosthetic osteolysis and aseptic loosening (Group C)
Exclusion criteria
Exclusion criteria: 1. Revision total hip arthroplasty (THA) surgery 2. Bilateral THA or hemiarthroplasty on the contra-lateral hip 3. Pre-existing other joint replacement 4. Inflammatory markers and intraoperative cultures indicating potential septic loosening 5. Cancer or immunodeficiency, patients receiving chemotherapy or immunosuppressive medication 6. Autoimmune diseases 7. Severe cognitive defects or psychiatric disorders 8. Inability to provide written informed consent to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative expression of miRNAs let-7i-5p, let-7e-5p, miR-15a-5p, miR-30a-3p, miR-130a-3p measured using real-time quantitative PCR (qRT-PCR) at baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Greece
Contacts
Public ContactSpyridon Papagiannis
Outcome results
None listed